Analysts Set DBV Technologies S.A. (NASDAQ:DBVT) PT at $35.38

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have earned an average rating of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $35.3750.

Several analysts have recently commented on DBVT shares. Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a research note on Monday, December 29th. HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a research note on Thursday, December 18th. Guggenheim reiterated a “buy” rating and set a $51.00 price objective (up from $35.00) on shares of DBV Technologies in a report on Wednesday, December 17th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Finally, Zacks Research raised shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a research report on Monday, September 29th.

Insiders Place Their Bets

In other DBV Technologies news, major shareholder Bpifrance Epic sold 2,076,990 shares of DBV Technologies stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total transaction of $10,073,401.50. Following the transaction, the insider directly owned 8,595,472 shares of the company’s stock, valued at $41,688,039.20. The trade was a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.44% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its stake in shares of DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after acquiring an additional 744 shares during the period. Millennium Management LLC lifted its holdings in DBV Technologies by 26.1% during the third quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock valued at $3,379,000 after purchasing an additional 69,849 shares during the last quarter. Citadel Advisors LLC purchased a new stake in DBV Technologies during the third quarter valued at about $220,000. Two Sigma Investments LP bought a new position in DBV Technologies during the third quarter worth about $167,000. Finally, DLD Asset Management LP purchased a new position in shares of DBV Technologies in the third quarter worth about $250,000. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Trading Up 8.4%

NASDAQ:DBVT opened at $18.80 on Tuesday. The stock has a market capitalization of $755.01 million, a price-to-earnings ratio of -3.64 and a beta of -1.17. The firm has a fifty day simple moving average of $16.53 and a two-hundred day simple moving average of $13.07. DBV Technologies has a 12 month low of $3.80 and a 12 month high of $26.18.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.